RJA
CLOV icon

Raymond James & Associates’s Clover Health Investments CLOV Stock Holding History

Raymond James & Associates’s Portfolio CLOV Stock Details CLOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,040
Closed -$39K – 4050
2022
Q1 		$39K Sell
11,040
-888
-7% -$2.58K ﹤0.01% 3939
2021
Q4 		$44K Buy
+11,928
New +$73.2K ﹤0.01% 3963
2021
Q2 		– Sell
-66,400
Closed -$502K – 4108
2021
Q1 		$502K Sell
66,400
-40,883
-38% -$461K ﹤0.01% 3020
2020
Q4 		$1.8M Buy
107,283
+79,461
+286% +$885K ﹤0.01% 1951
2020
Q3 		$347K Buy
27,822
+10,105
+57% +$112K ﹤0.01% 2865
2020
Q2 		$195K Buy
+17,717
New +$191K ﹤0.01% 3140

Other funds holding CLOV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's CLOV Position: Q2 2022 in Review

Raymond James & Associates sold out of Clover Health Investments (CLOV) in Q2 2022, closing a stake of 11,040 shares — an estimated $39K sold.

Raymond James & Associates first reported a position in CLOV in Q2 2020 and held it in 6 quarters. The position peaked at $1.8M in Q4 2020. 176 funds tracked by Wall St. Rank hold CLOV as of Q2 2022.

  • Raymond James & Associates reported no remaining Clover Health Investments position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 11,040 Clover Health Investments shares in Q2 2022, an estimated $39K.
  • Raymond James & Associates first reported a position in Clover Health Investments in Q2 2020 and held it in 6 quarters.
  • Raymond James & Associates's Clover Health Investments position peaked at $1.8M in Q4 2020.
  • 176 funds tracked by Wall St. Rank held Clover Health Investments as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.